KR100613528B1 - Ｃｃｒ5 길항제, 및 이를 포함하는 약제학적 조성물 및 키트 - Google Patents

Ｃｃｒ5 길항제, 및 이를 포함하는 약제학적 조성물 및 키트 Download PDF

Info

Publication number
KR100613528B1
KR100613528B1 KR1020037012565A KR20037012565A KR100613528B1 KR 100613528 B1 KR100613528 B1 KR 100613528B1 KR 1020037012565 A KR1020037012565 A KR 1020037012565A KR 20037012565 A KR20037012565 A KR 20037012565A KR 100613528 B1 KR100613528 B1 KR 100613528B1
Authority
KR
South Korea
Prior art keywords
alkyl
group
phenyl
formula
reverse transcriptase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020037012565A
Other languages
English (en)
Korean (ko)
Other versions
KR20030083014A (ko
Inventor
밀러마이클더블유.
Original Assignee
쉐링 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쉐링 코포레이션 filed Critical 쉐링 코포레이션
Publication of KR20030083014A publication Critical patent/KR20030083014A/ko
Application granted granted Critical
Publication of KR100613528B1 publication Critical patent/KR100613528B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
KR1020037012565A 2001-03-29 2002-03-27 Ｃｃｒ5 길항제, 및 이를 포함하는 약제학적 조성물 및 키트 Expired - Fee Related KR100613528B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27993801P 2001-03-29 2001-03-29
US60/279,938 2001-03-29
PCT/US2002/009491 WO2002079194A1 (en) 2001-03-29 2002-03-27 Ccr5 antagonists useful for treating aids

Publications (2)

Publication Number Publication Date
KR20030083014A KR20030083014A (ko) 2003-10-23
KR100613528B1 true KR100613528B1 (ko) 2006-08-16

Family

ID=23070981

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037012565A Expired - Fee Related KR100613528B1 (ko) 2001-03-29 2002-03-27 Ｃｃｒ5 길항제, 및 이를 포함하는 약제학적 조성물 및 키트

Country Status (29)

Country Link
US (5) US6720325B2 (enExample)
EP (2) EP1591444B1 (enExample)
JP (2) JP4248251B2 (enExample)
KR (1) KR100613528B1 (enExample)
CN (1) CN100519554C (enExample)
AR (1) AR033452A1 (enExample)
AT (2) ATE466009T1 (enExample)
AU (1) AU2002255947B8 (enExample)
BR (1) BR0208398A (enExample)
CA (1) CA2442227C (enExample)
CZ (1) CZ20032636A3 (enExample)
DE (2) DE60236218D1 (enExample)
DK (1) DK1373256T3 (enExample)
ES (2) ES2242856T3 (enExample)
HU (1) HUP0400349A3 (enExample)
IL (1) IL157551A0 (enExample)
MX (1) MXPA03008853A (enExample)
MY (1) MY128609A (enExample)
NO (1) NO326349B1 (enExample)
NZ (1) NZ527768A (enExample)
PE (1) PE20020996A1 (enExample)
PL (1) PL364560A1 (enExample)
PT (1) PT1373256E (enExample)
RU (1) RU2316553C2 (enExample)
SI (1) SI1373256T1 (enExample)
SK (1) SK287521B6 (enExample)
TW (1) TWI237638B (enExample)
WO (1) WO2002079194A1 (enExample)
ZA (1) ZA200307474B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1373256T3 (da) * 2001-03-29 2005-10-10 Schering Corp CCR5-antagonister, der er nyttige til behandling af AIDS
CN1545509A (zh) 2001-07-02 2004-11-10 用作趋化因子受体活性调节剂的哌啶衍生物
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
TW200504033A (en) 2002-10-23 2005-02-01 Procter & Gamble Melanocortin receptor ligands
DE60324014D1 (de) * 2002-12-13 2008-11-20 Smithkline Beecham Corp Heterocyclische verbindungen alsccr5-antagonisten
PE20040769A1 (es) * 2002-12-18 2004-11-06 Schering Corp Derivados de piperidina utiles como antagonisas ccr5
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
US7652142B2 (en) * 2003-11-03 2010-01-26 Schering Corporation Bipiperidinyl derivatives useful as inhibitors of chemokine receptors
CN1946402A (zh) * 2004-02-05 2007-04-11 先灵公司 用作ccr3拮抗剂的哌啶衍生物
SE0400925D0 (sv) * 2004-04-06 2004-04-06 Astrazeneca Ab Chemical compounds
BRPI0509803A (pt) * 2004-04-13 2007-09-18 Incyte Corp derivados de piperazinilpiperidina como antagonistas de receptor de quimiocina
TWI400232B (zh) * 2004-09-13 2013-07-01 Ono Pharmaceutical Co 含氮雜環衍生物及以該含氮雜環衍生物為有效成分之藥劑
WO2006071875A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
JP2008526862A (ja) * 2005-01-06 2008-07-24 シェーリング コーポレイション ピペラジン化合物の薬学的な塩の調製
JP2008526863A (ja) * 2005-01-06 2008-07-24 シェーリング コーポレイション Ｃｃ５ｒ受容体アンタゴニストの合成
CA2598568A1 (en) 2005-02-23 2006-08-31 Schering Corporation Piperidinyl piperidine derivatives useful as inhibitors of chemokine receptors
MX2007010258A (es) * 2005-02-23 2007-09-11 Schering Corp Derivados de piperidinil piperazina utiles como inhibidores de receptores de quimiocina.
KR20080037655A (ko) 2005-07-21 2008-04-30 아스트라제네카 아베 신규 피페리딘 유도체
US7462485B2 (en) * 2005-10-07 2008-12-09 Glaser Lawrence F Modified erythrocytes and uses thereof
TW200745087A (en) * 2006-02-24 2007-12-16 Schering Corp CCR5 antagonists useful for treating HIV
WO2008030853A2 (en) * 2006-09-06 2008-03-13 Incyte Corporation Combination therapy for human immunodeficiency virus infection
US20100063280A1 (en) * 2006-12-22 2010-03-11 Schering Corporation Process for preparing ccr-5 receptor antagonists utilizing 4-substituted 1-cyclopropane-sulfonyl-piperidinyl compounds
WO2009111218A2 (en) * 2008-02-29 2009-09-11 Schering Corporation Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5368854A (en) 1992-08-20 1994-11-29 Schering Corporation Use of IL-10 to treat inflammatory bowel disease
WO1994018192A1 (en) 1993-02-12 1994-08-18 Merck & Co., Inc. Piperazine derivatives as hiv protease inhibitors
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
KR100424989B1 (ko) 1995-06-07 2004-06-16 킴벌리-클라크 월드와이드, 인크. 흡수용품에서세균분비단백질의억제방법
NZ321575A (en) 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
US5952349A (en) 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
US5977138A (en) 1996-08-15 1999-11-02 Schering Corporation Ether muscarinic antagonists
WO1999004794A1 (en) 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
US6066636A (en) 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
EP1013276A1 (en) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
PT1175402E (pt) * 1999-05-04 2005-11-30 Schering Corp Derivados da piperidina uteis como antagonistas ccr5
CA2371583C (en) 1999-05-04 2005-09-13 Schering Corporation Piperazine derivatives useful as ccr5 antagonists
DK1373256T3 (da) * 2001-03-29 2005-10-10 Schering Corp CCR5-antagonister, der er nyttige til behandling af AIDS

Also Published As

Publication number Publication date
DE60236218D1 (de) 2010-06-10
DE60204951D1 (de) 2005-08-11
US20050059666A1 (en) 2005-03-17
NO326349B1 (no) 2008-11-17
AU2002255947B8 (en) 2005-11-17
EP1373256B1 (en) 2005-07-06
US7008946B2 (en) 2006-03-07
IL157551A0 (en) 2004-03-28
CZ20032636A3 (cs) 2003-12-17
EP1591444A1 (en) 2005-11-02
JP2008074862A (ja) 2008-04-03
PE20020996A1 (es) 2002-11-01
RU2003131879A (ru) 2005-05-10
EP1591444B1 (en) 2010-04-28
ATE299139T1 (de) 2005-07-15
CN1547580A (zh) 2004-11-17
SI1373256T1 (sl) 2005-12-31
NO20034311L (no) 2003-11-26
ES2242856T3 (es) 2005-11-16
NZ527768A (en) 2005-03-24
CA2442227A1 (en) 2002-10-10
TWI237638B (en) 2005-08-11
US20040157854A1 (en) 2004-08-12
SK287521B6 (sk) 2010-12-07
US6900211B2 (en) 2005-05-31
HUP0400349A2 (hu) 2004-12-28
HK1057363A1 (en) 2004-04-02
CN100519554C (zh) 2009-07-29
BR0208398A (pt) 2004-06-15
MXPA03008853A (es) 2003-12-04
AU2002255947B2 (en) 2005-10-27
MY128609A (en) 2007-02-28
DK1373256T3 (da) 2005-10-10
JP4248251B2 (ja) 2009-04-02
US20050143390A1 (en) 2005-06-30
RU2316553C2 (ru) 2008-02-10
AR033452A1 (es) 2003-12-17
ZA200307474B (en) 2004-12-24
US20030008877A1 (en) 2003-01-09
SK11962003A3 (sk) 2004-03-02
HUP0400349A3 (en) 2010-03-29
US7098213B2 (en) 2006-08-29
WO2002079194A1 (en) 2002-10-10
CA2442227C (en) 2008-10-28
ES2342942T3 (es) 2010-07-19
US7060701B2 (en) 2006-06-13
JP2004525157A (ja) 2004-08-19
DE60204951T2 (de) 2006-05-11
PT1373256E (pt) 2005-11-30
NO20034311D0 (no) 2003-09-26
KR20030083014A (ko) 2003-10-23
HK1083505A1 (en) 2006-07-07
ATE466009T1 (de) 2010-05-15
US20060063771A1 (en) 2006-03-23
EP1373256A1 (en) 2004-01-02
PL364560A1 (en) 2004-12-13
US6720325B2 (en) 2004-04-13

Similar Documents

Publication Publication Date Title
KR100613528B1 (ko) Ｃｃｒ5 길항제, 및 이를 포함하는 약제학적 조성물 및 키트
KR100439357B1 (ko) Ｃｃｒ５ 길항제로서 유용한 피페리딘 유도체
JP4223950B2 (ja) Ｃｃｒ５アンタゴニストとして有用なピペリジン誘導体
AU2002255947A1 (en) CCR5 antagonists useful for treating AIDS
EP1632479A2 (en) Piperazine derivatives useful as ccr5 antagonists
KR20030083015A (ko) Ｃｃｒ5 길항제로서 유용한 아릴 옥심-피페라진
KR20080098541A (ko) Ｈｉｖ 치료에 유용한 ｃｃｒ5 길항제
HK1057363B (en) Ccr5 antagonists useful for treating aids
HK1083505B (en) Ccr5 antagonists useful for treating aids
HK1061563B (en) Piperidine derivatives useful as ccr5 antagonists for the treatment of hiv

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20100729

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20110810

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20110810

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000